A long-acting immunotherapy adapted to cats, targeting the neurogenic inflammation behind chronic itch and skin inflammation.
Feline atopic skin syndrome is a chronic, relapsing pruritic disease that presents as self-induced hair loss, miliary dermatitis, eosinophilic lesions or intense itching of the head and neck. Long-term control relies on corticosteroids or immunosuppressants, which are difficult to sustain in cats over years.
In cats, as in dogs, chronic itch is sustained by a loop between sensory nerves, mast cells and inflammatory mediators. Xep04 applies the platform to that loop in feline skin, with an immunogen adapted to the cat.
How the platform works →Protocols, study reports and the regulatory package are available to qualified partners under confidentiality.
